Compare CCSI & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCSI | CSTL |
|---|---|---|
| Founded | 2021 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 648.0M | 722.8M |
| IPO Year | 2022 | 2019 |
| Metric | CCSI | CSTL |
|---|---|---|
| Price | $37.39 | $33.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $42.25 | ★ $45.22 |
| AVG Volume (30 Days) | 84.7K | ★ 319.5K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.72 | N/A |
| Revenue | ★ $349,696,000.00 | $344,229,000.00 |
| Revenue This Year | $3.01 | $8.49 |
| Revenue Next Year | $3.66 | $10.44 |
| P/E Ratio | $13.58 | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $20.20 | $17.72 |
| 52 Week High | $41.40 | $44.28 |
| Indicator | CCSI | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 54.95 | 47.52 |
| Support Level | $32.99 | $31.44 |
| Resistance Level | $38.38 | $34.23 |
| Average True Range (ATR) | 1.21 | 1.69 |
| MACD | 0.13 | -0.13 |
| Stochastic Oscillator | 85.71 | 21.52 |
Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in the fax cloud business. The company's offerings include communication, data extraction, and digital signature solutions that enable users to securely access, exchange, and manage information across organizational and geographic boundaries. It serves multiple industry verticals, including healthcare, government, financial services, legal, and education. Geographically, the company operates in the United States, Canada, Ireland, and other countries. It derives the maximum revenue from the United States.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.